Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group
Several studies demonstrate the efficacy of short- and long-term Sandostatin® treatment in acromegaly administered subcutaneously at doses ranging from 150 to 300 µg up to 600 µg per day [1, 3, 5, 7–10]. A rhythm of 3 injections per day has been shown to reduce the magnitude of the re-elevation of growth hormone (GH) which occurs before the following injection when Sandostatin is given only twice daily. However, some patients fail to respond adequately to the above-mentioned doses thus pointing to the possible need for higher doses of Sandostatin  or continuous subcutaneous infusion.
KeywordsDepression Carbohydrate Adenoma Diarrhea Gall
Unable to display preview. Download preview PDF.
- 2.Chanson P, Timsit J, Benoit O, Augendre B, Boulonguet M, Guillausseau PJ, Warnet A, Lubetzki J (1968) Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet ii: 1270–1271Google Scholar
- 9.Lamberts SWJ, Uitterlinden P. Verschoor L, van Dongen KJ, Del Pozo E (1985) Longterm treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576— 1580Google Scholar
- 10.Plewe G, Beyer J, Krause U, Neufeld M, Del Pozo E (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet II: 782–784Google Scholar